Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$2.16 USD
-0.06 (-2.70%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Amylyx Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 49.27 | -198.38 | -87.93 | -42.28 | NA |
Depreciation/Amortization & Depletion | -8.85 | -1.57 | 0.17 | 0.00 | NA |
Net Change from Assets/Liabilities | -65.66 | -1.64 | 4.60 | 2.60 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 37.16 | 21.71 | 8.36 | 2.98 | NA |
Net Cash From Operating Activities | 11.92 | -179.87 | -74.80 | -36.70 | NA |
Property & Equipment | -1.24 | -2.53 | -0.35 | -0.15 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 93.29 | -236.46 | -46.05 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | 92.05 | -238.99 | -46.41 | -0.15 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.99 | 434.64 | 135.34 | 30.01 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 25.90 | 16.82 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -3.45 | -2.85 | -2.73 | 0.00 | NA |
Net Cash from Financing Activities | 3.54 | 431.79 | 158.51 | 46.82 | NA |
Effect of Exchange Rate Changes | 0.16 | -0.07 | 0.01 | 0.00 | NA |
Net Change In Cash & Equivalents | 107.68 | 12.87 | 37.31 | 9.98 | NA |
Cash at Beginning of Period | 63.25 | 50.38 | 13.07 | 3.09 | NA |
Cash at End of Period | 170.92 | 63.25 | 50.38 | 13.07 | NA |
Diluted Net EPS | 0.70 | -3.39 | -13.35 | NA | NA |
Fiscal Year End for Amylyx Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -191.49 | -118.79 | 49.27 | 44.54 | 23.65 |
Depreciation/Amortization & Depletion | -5.24 | -2.27 | -8.85 | -6.58 | -4.40 |
Net Change from Assets/Liabilities | -8.53 | 0.16 | -65.66 | -67.22 | -33.16 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 138.19 | 120.41 | 37.16 | 27.63 | 17.45 |
Net Cash From Operating Activities | -67.07 | -0.49 | 11.92 | -1.63 | 3.54 |
Property & Equipment | -0.16 | -0.07 | -1.24 | -0.89 | -0.53 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -27.99 | 0.89 | 93.29 | 72.01 | 179.74 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -28.14 | 0.82 | 92.05 | 71.13 | 179.22 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.49 | 1.45 | 6.99 | 6.65 | 5.66 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.34 | -1.32 | -3.45 | -3.33 | -3.24 |
Net Cash from Financing Activities | 0.16 | 0.13 | 3.54 | 3.31 | 2.42 |
Effect of Exchange Rate Changes | -0.15 | -0.11 | 0.16 | -0.08 | 0.06 |
Net Change In Cash & Equivalents | -95.20 | 0.35 | 107.68 | 72.73 | 185.23 |
Cash at Beginning of Period | 170.92 | 170.92 | 63.25 | 63.25 | 63.25 |
Cash at End of Period | 75.72 | 171.27 | 170.92 | 135.98 | 248.48 |
Diluted Net EPS | -1.07 | -1.75 | 0.07 | 0.30 | 0.31 |